Neurochemical Mechanisms in Disease P38 ppsx

Trinucleotide-Expansion Diseases 355 Park SC, Yeo EJ, Han JA, Hwang YC, Choi JY, Park JS, Park YH, Kim KO, Kim IG, Seong SC, Kwak SJ (1999) Aging process is accompanied by increase in transglutaminase C. J Gerentol A Biol Sci Med 54:B78–B83 Pearson CE, Nichol Edamura K, Cleary JD (2005) Repeat instability: mechanisms of dynamic mutations. Nature Rev Genet 6:729–742 Perutz MF, Johnson T, Suzuki M, Finch JT (1994) Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci USA 91: 5355–5358 Perutz MF, Windle AH (2001) Cause of neural death in neurodegenerative diseases attributable to expansion of glutamine repeats. Nature 412:143–144 Pinto JT, Van Raamsdonk J, Leavitt BR, Hayden MR, Thaler HT, Jeitner TM, Krasnikov BF, Cooper AJL (2005) Treatment of YAC128 mice with cystamine does not lead to its accumu- lation in plasma or brain: implications for the treatment of Huntington disease. J Neurochem 94:1087–1101 Quintanilla RA, Johnson GVW (2009) Role of mitochondrial dysfunction in the pathogenesis of Huntington’s disease. Brain Res Bull 80:242–247 Ratovitski T, Gucek M, Jiang H, Chighladze E, Waldron E, D’Ambola J, Hou Z, Liang Y, Poirier MA, Hirschhorn RR, Graham R, Hayden MR, Cole RN, Ross CA (2009) Mutant huntingtin N-terminal fragments of specific size mediate aggregation and toxicity in neuronal cells. J Biol Chem 284:10855–10867 Reddy PH, Mao P, Manczak M (2009) Mitochondrial structural and functional dynamics in Huntington’s disease. Brain Res Rev 61:33–48 Renna M, Jimenez-Sanchez M, Sarkar S, Rubinsztein DC (2010) Chemical inducers of autophagy that enhance the clearance of mutant proteins in neurodegenerative diseases. J Biol Chem 285:11061–11067 Restituito S, Thompson RM, Eliet J, Raike RS, Riedl M, Charnet P, Gomez CM (2000) The polyglutamine expansion in spinocerebellar ataxia t ype 6 causes a β subunit specific enhanced activation of P/Q-type calcium channels in Xenopus oocytes. J Neurosci 20:6394–6403 Rodrigues GG, Walker RH, Brice A, Cazeneuve C, Russaouen O, Teive HA, Munhoz RP, Becker N, Raskin S, Werneck LC, Junior WM, Tumas V (2008) Huntington’s disease-like 2 in Brazil – report of 4 patients. Mov Disord 23:2244–2247 Rolfs A, Koeppen AH, Bauer I, Bauer P, Buhlmann S, Topka H, Schöls L, Riess O (2003) Clinical features and neuropathology of autosomal dominant spinocerebellar ataxia (SCA17). Ann Neurol 54:367–373 Rose C, Menzies FM, Renna M, Acevedo-Arozena A, Corrochano S, Sadiq O, Brown SD, Rubinsztein DC (2010) Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington’s disease. Hum Mol Genet 2010 Mar 17. [Epub ahead of print] Rosenberg RN (1996) DNA-triplet repeats and neurologic disease. New Engl J Med 335: 1222–1224 Ross CA (2002) Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington’s disease and related disorders. Neuron 35:819–822 Ross CA, Poirier MA (2004) Protein aggregation and neurodegenerative disease. Nat Med 10: S10–S17 Ross CA, Shoulson I (2009) Huntington disease. pathogenesis, biomarkers, and approaches to experimental therapeutics. Parkinsonism Rel Disord 15:S135–S138 Rüb U, Brunt ER, Deller T (2008) New insights into the pathoanatomy of spinocerebellar ataxia type 3 (Machado-Joseph disease). Curr Opin Neurol 21:111–116 Sarafidou T, Kahl C, Martinez-Garay I, Mangelsdorf M, Gesk S, Baker E, Kokkinaki M, Talley P, Maltby EL, French L, Harder L, Hinzmann B, Nobile C, Richkind K, Finnis M, Deloukas P, Sutherland GR, Kutsche K, Moschonas NK, Siebert R, Gécz J, and European Collaborative Consortium for the Study of ADLTE (2004) Folate-sensitive fragile site FRA10A is due to an expansion of a CGG repeat in a novel gene FRA10AC1, encoding a nuclear protein. Genomics 84:69–81 356 A.J.L. Cooper and J.P. Blass Sato N, Amino T, Kobayashi K, Asakawa S, Ishiguro T, Tsunemi T, Takahashi M, Matsuura T, Flanigan KM, Iwasaki S, Ishino F, Saito Y, Murayama S, Yoshida M, Hashizume Y, Takahashi Y, Tsuji S, Shimizu N, Toda T, Ishikawa K, Mizusawa H (2009) Spinocerebellar ataxia type 31 is associated with “inserted” penta-nucleotide repeats containing (TGGAA) n .AmJHum Genet 85:544–557 Saudou F, Finkbeiner S, Devys D, Greenberg ME (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95:55–66 Sawa A (2001) Mechanisms for neuronal cell death and dysfunction in Huntington’s disease: pathological cross-talk between the nucleus and the mitochondria? J Mol Med 79:375–381 Schaffar G, Breuer P, Boteva R, Behrends C, Tzvetkov N, Strippel N, Sakahira H, Siegers K, Hayer- Hartl M, Hartl FU (2004) Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol Cell 15:95–105 Scherzinger E, Sittler A, Schweiger K, Heiser V, Lurz R, Hasenbank R, Bates GP, Lehrach H, Wanker EE (1999) Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington’s disease pathology. Proc Natl Acad Sci USA 96:4604–4609 Schilling G, Savonenko AV, Klevytska A, Morton JL, Tucker SM, Poirier M, Gale A, Chan N, Gonzales V, Slunt HH, Coonfield ML, Jenkins NA, Copeland NG, Ross CA, Borchelt DR (2004) Nuclear-targeting of mutant huntingtin fragments produces Huntington’s disease-like phenotypes in transgenic mice. Hum Mol Genet 13:1599–1610 Schweitzer JK, Krivda JP, D’Souza-Schorey C (2009) Neurodegeneration in Niemann-Pick Type C disease and Huntington’s disease: impact of defects in membrane trafficking. Curr Drug Targets 10:653–665 Seidel K, Brunt ER, de Vos RA, Dijk F, van der Want HJ, Rüb U, den Dunnen WF (2009) The p62 antibody reveals various cytoplasmic protein aggregates in spinocerebellar ataxia type 6. Clin Neuropathol 28:344–349 Serra HG, Byam CE, Lande JD, Tousey SK, Zoghbi HY, Orr HT (2004) Gene profiling links SCA1 pathophysiology to glutamate signaling in Purkinje cells of transgenic mice. Hum Mol Genet 13:2535–2543 Sharma R, De Biase I, Gómez M, Delatycki MB, Ashizawa T, Bidichandani SI (2004) Friedreich ataxia in carriers of unstable borderline GAA triplet-repeat alleles. Ann Neurol 56:898–901 Shelbourne P, Johnson K (1992) Myotonic dystrophy: another case of too many repeats? Hum Mutat 1:183–189 Shoesmith Berke SJ, Flores Schmied FA, Brunt ER, Ellerby LM, Paulson HL (2004) Caspase- mediated proteolysis of the polyglutamine disease protein ataxin-3. J Neurochem 89:908–918 Smith R, Bacos K, Fedele V, Soulet D, Walz HA, Obermüller S, Lindqvist A, Björkqvist M, Klein P, Onnerfjord P, Brundin P, Mulder H, Li JY (2009) Mutant huntingtin interacts with β-tubulin and disrupts vesicular transport and insulin secretion. Hum Mol Genet 18:3942–3954 Spindler M, Beal MF, Henchcliffe C (2009) Coenzyme Q10 effects in neurodegenerative diseases. Neuropsychiatr Dis Treat 5:597–610 Steffan JS, Arawal N, Pallos J, Rockabrand E, Trotman LC, Slepko N, Illes K, Lukacsovich T, Zhu YZ, Cattaneo E, Pandolfi PP, Thompson LM, Marsh JL (2004) SUMO modification and Huntington’s disease pathology. Science 304:100–104 Strelnikov V, Nemtsova M, Chesnokova G, Kuleshov N, Zaletayev D (1999) A simple multiplex FRAXA FRAXE, and FRAXF PCR assay convenient for wide screening programs. Hum Mutat 13:166–169 Su B, Wang X, Zheng L, Perry G, Smith MA, Zhu X (2010) Abnormal mitochondrial dynamics and neurodegenerative diseases. Biochim Biophys Acta 1892:135–142 Sugars KL, Rubinsztein DC (2003) Transcriptional abnormalities in Huntington disease. Trends Genet 19:233–238 Sutherland GR (1979a) Heritable fragile sites on human chromosomes. I. Factors affecting expression in lymphocyte culture. Am J Hum Genet 31:125–135 Trinucleotide-Expansion Diseases 357 Sutherland GR (1979b) Heritable fragile sites on human chromosomes. II. Distribution, phenotypic effects, and cytogenetics. Am J Hum Genet 31:136–148 Sutherland GR (2003) Rare fragile sites. Cytogenet Genome Res 100:77–84 Suzuki K, Kastuno M, Banno H, Sobue G (2009) Pathogenesis-targeting therapeutics for spinal and bulbar muscular atrophy (SBMA). Neuropathology 29:509–516 Tabrizi SJ, Cleeter MW, Xuereb J, Taanman JW, Cooper JM, Schapira AH (1999) Biochemical abnormalities and excitotoxicity in Huntington’s disease brain. Ann Neurol 45:25–32 Tabrizi SJ, Workman J, Hart PE, Mangiarini L, Mahal A, Bates G, Cooper JM, Schapira AH (2000) Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann Neurol 47:80–86 The Huntington Disease Collaborative Research Group. (1993) A novel gene containing a trin- ucleotide repeat that is expanded and unstable on Huntington disease chromosome. Cell 72:971–983 Uitti RJ (1994) Cerebellar degenerations. In neurodegenerative diseases. In: Calne DB (ed) Neurodegenerative diseases. W. B. Saunders Company, New York, NY, pp 787–806 Van Raamsdonk JM, Pearson J, Bailey CDC, Rogers DA, Johnson GVW, Hayden MR, Leavitt BR (2005) Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. J Neurochem 95:210–220 Vincent JB, Yuan QP, Schalling M, Adolfsson R, Azevedo MH, Macedo A, Bauer A, DallaTorre C, Medeiros HM, Pato MT, Pato CN, Bowen T, Guy CA, Owen MJ, O’Donovan MC, Paterson AD, Petronis A, Kennedy JL (2000) Long repeat tracts in major psychosis. Am J Med Genet (Neuropsychiatric Genetics) 96:873–876 Wakamiya M, Matsuura T, Liu Y, Schuster GC, Gao R, Xu W, Sarkar PS, Lin X, Ashizawa T (2006) The role of ataxin 10 in the pathogenesis of spinocerebellar ataxia type 10. Neurology 67:607–613 Wang J, Wang CE, Orr A, Tydlacka S, Li SH, Li XJ (2008) Impaired ubiquitin-proteasome system activity in the synapses of Huntington’s disease mice. J Cell Biol 180:1177–1189 Wang X, Wang H, Xia Y, Jiang H, Shen L, Wang S, Shen R, Xu Q, Luo X, Tang B (2010) Spinocerebellar ataxia type 6: systematic patho-anatomical study reveals different phyloge- netically defined regions of the cerebellum and neural pathways undergo different evolutions of the degenerative process. Neuropathology 2010 Jan 26. [Epub ahead of print] Waragai M, Lammers CH, Takeuchi S, Imafuku I, Udagawa Y, Kanazawa I, Kawabata M, Mouradian MM, Okazawa H (1999) PQBP-1, a novel polyglutamine tract-binding pro- tein, inhibits transcription activation by BRn-2 and affects cell survival. Hum Mol Gent 8: 977–987 Warby SC, Doty CN, Graham RK, Shively J, Singaraja RR, Hayden MR (2009) Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments. Mol Cell Neurosci 40: 121–127 The US – Venezuela Collaborative Research Project and Wexler NS (2004) Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington’s disease age of onset. Proc Natl Acad Sci USA 101:3498–3503 Wu LL, Fan Y, Li S, Li XJ, Zhou XF (2010) Huntingtin-associated protein-1 interacts with pro-brain-derived neurotrophic factor and mediates its transport and release. J Biol Chem 285:5614–5623 Xifró X, Giralt A, Saavedra A, García-Martínez JM, Díaz-Hernández M, Lucas JJ, Alberch J, Pérez-Navarro E (2009) Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington’s disease: role in excitotoxicity. Neurobiol Dis 36:461–469 Zainelli GM, Dudeck NL, Ross CA, Kim SY, Muma NA (2005) Mutant huntingtin protein: a substrate for transglutaminase 1, 2, and 3. J Neuropathol Exp Neurol 64:58–65 Zainelli GM, Ross CA, Troncos JC, Muma NA (2003) Transglutaminase cross-links in intranuclear inclusions in Huntington disease. J Neuropathol Exp Neurol 62:14–24 Zalfa F, Bagni C (2004) Molecular insights into mental retardation: multiple functions for the fragile X mental retardation protein? Curr Issues Mol Biol 6:73–88 358 A.J.L. Cooper and J.P. Blass Zhuchenko O, Bailey J, Bonnen P, Ashizawa T, Stockton DW, Amos C, Dobyns WB, Subramony SH, Zoghbi HY, Lee CC (1997) Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the α 1A -voltage-dependent calcium channel. Nat Genet 15:62–69 Zoghbi HY, Orr HT (2009) Pathogenic mechanisms of a polyglutamine-mediated neurodegenera- tive disease, spinocerebellar ataxia type 1. J Biol Chem 284:7425–7429 Zoltewicz JS, Stewart NJ, Leung R, Peterson AS (2004) Atrophin 2 recruits histone deacylase and is required for the function of multiple signaling centers during mouse embryogenesis. Development 131:3–14 Zuccato C, Tartari M, Crotti A, Goffredo D, Valenza M, Coni L, Cataudella T, Leavitt BR, Hayden MR, Timmusk T, Rigamonti D, Cattaneo E (2003) Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Gen 35:76–83 CNS Cytokines Jane Kasten-Jolly and David A. Lawrence Abstract The first description of the inflammatory process appeared as early as the first century AD. Among the first things learned about inflammation is that vascu- lar permeability is increased and leukocyte extravasation occurs. It is now realized that the central nervous system (CNS) is not as devoid of immune cell entrance as once believed and that neuroinflammation can occur. Even in the CNS absence of peripheral immune cells, cytokines from the periphery can influence glial acti- vation in response to endogenous or exogenous stresses. Activated glial cells will secrete proinflammatory cytokines among other factors. The presence of relatively high concentrations of proinflammatory cytokines, such as IL-1, IL-6, and TNF-α,in the brain produces sickness behavior. Neuroinflammation is not only caused by viral or bacterial infection, but can also be the result of physical injury or neurodegener- ative diseases, such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and cerebral palsy. This chronic neuroinflammation is associated with a number of common factors; most notable among these is the increased concentration of proin- flammatory cytokines. In addition to the ones listed above, others have been detected including, IL-18, IL-33, and HMGB1. Although TGF-β1 functions most often as an anti-inflammatory cytokine, under certain circumstances it, too, can have proinflam- matory activity. Other common features of neuroinflammation include increased production of reactive oxygen species (ROS) and nitric oxide (NO), which func- tion to increase apoptosis and promote neuronal damage. Activation of astrocytes is detected by elevated GFAP expression. Activated astrocytes promote chemokine expression causing permeability of the blood–brain barrier (BBB), thus allowing leukocytes to enter the brain tissue. The heavy metal Pb accumulates in glial cells and in doing so can potentiate cytokine and glutamate-mediated increases in the BBB permeability, as well as cause chronic glial cell activation. Pb’s ability to promote gliosis and deficiencies in chaperone protein function has prompted a com- parison of Pb toxicity to certain neurodegenerative disorders, such as Alzheimer’s D.A. Lawrence (B) New York State Department of Health, Wadsworth Center, Albany, NY 12201, USA e-mail: david.lawrence@wadsworth.org 359 J.P. Blass (ed.), Neurochemical Mechanisms in Disease, Advances in Neurobiology 1, DOI 10.1007/978-1-4419-7104-3_12, C  Springer Science+Business Media, LLC 2011 360 J. Kasten-Jolly and D.A. Lawrence and Parkinson’s diseases. Toxicity of other metals, such as, Al, Cu, Cd, Zn, and Hg was also found to share common features with Alzheimer’s disease. Keywords Alzheimer’s disease · Astrocytes · Blood–brain barrier (BBB) · Central nervous system (CNS) · Chaperone proteins · Chemokines · Cytokines · Heavy met- als · Inflammation · Lead (Pb) · Map kinases · Microglia · Neurons · Nitric oxide (NO) · Reactive oxygen species (ROS) Contents 1 Introduction 360 1.1 Cytokines and Neuroinflammation 361 1.2 MAP Kinases and Stress Kinases 366 1.3 Microglia Cells 368 1.4 Astrocytes 369 1.5 Neuroinflammatory Aspects of Pb Toxicity 369 1.6 Neuroinflammatory Effects of Metals Other than Pb 372 2 Summary 374 References 375 1 Introduction The inflammatory process was first described by Cornelius Celsus in the first cen- tury AD when he listed the four signs of inflammation: rubor et tumor cum calore et dolore (redness and swelling with heat and pain). A fifth sign of inflammation has been annexed to the cardinal four, functio laesa (disruption of normal func- tion); although its origin has been questioned (Rather, 1971), it is the disturbance of normal function that may lead to the potential pathological consequences of inflam- mation. The original four signs of inflammation were based mainly on peripheral skin observations. It wasn’t until the nineteenth and twentieth centuries that the cel- lular aspects of inflammation began to be understood. Julius Cohnheim observed that in the inflamed tissue there was increased vasodilation along with vascular per- meability and leukocyte extravasation. Sir Thomas Lewis noted that the vascular changes were mediated by chemical substances present in serum (Cotran et al., 1994). It was not realized until much later that inflammation could occur in hid- den places, such as the central nervous system (CNS) and that inflammation could be initiated by endogenous or exogenous agents. With advancements in molecu- lar and cellular methodology during the past few decades, much has been learned about the mediators of the inflammation process. Much of this knowledge has been obtained through the study of disease-related inflammation (Sheng et al., 1996; Akiyama et al., 2000; Combs et al., 2000; Cagnin et al., 2002; Rosales-Corral et al., 2004; Eikekenboom et al., 2006; Shepherd et al., 2006; Zipp and Aktas, 2006; Lassmann, 2007), injury, and animal models (Jafarian-Tehrani and Sternberg, 1999; CNS Cytokines 361 Kielian and Hickey, 2000). Although inflammation usually has positive influences in defense against pathogens, the processes can cause cellular damage and initiate or exacerbate various pathologies, especially autoimmune diseases and neurobehav- ioral diseases in susceptible humans and animals. Inflammation is closely associated with oxidative stress, and chronic inflammation along with its accompanying oxi- dant damage can lead to an acceleration of aging-related changes, which includes cytotoxicity (Norris et al., 2005). The present chapter is restricted to discussion of neuroinflammation, including information about the roles of cytokine, chemokines, MAP kinases, glia, and reactive oxygen species. Closing paragraphs present a dis- cussion of metal neurotoxicity, with emphasis on the immune- and neurotoxicant lead (Pb), and the neuroinflammatory aspects of this toxicity. 1.1 Cytokines and Neuroinflammation 1.1.1 Interleukin (IL)-1, IL-6, and TNF-α The proinflammatory cytokines, IL-6, IL-1β, and TNF-α, are associated with sick- ness behavior and their levels increase in the CNS during viral or bacterial infections (Quan et al., 1999; Pollmacher et al., 2002; Anisman, 2004; Dantzer et al., 2007; 2008). The sickness behavior paradigm of lethargy (malaise and lack of mobility), loss of appetite and drinking, and altered body temperature (fever) is due to the sig- nals of proinflammation cytokines delivered to the hypothalamus (Woiciechowsky et al., 1999). The brain monitors peripheral innate immune responses by several methods (Quan and Banks, 2007). One pathway involves activation of afferent nerves by locally produced cytokines and pathogen-associated molecular patterns (PAMPs), such as vagal nerve, during an abdominal infection. A second mech- anism involves the humoral (antibody-mediated) pathway and Toll-like receptors (TLRs) located on macrophage-like cells residing in the circumventricular organs and the choroid plexus (Rao et al., 2005). These cells respond to immune complexes of antibody:antigen and PAMPs by producing proinflammatory cytokines. These cytokines then enter the brain by volume diffusion. Third, the overflow of cytokines in the systemic circulation can gain entry to the brain via cytokine transporters at the blood–brain barrier (Matyszak, 1998; Karman et al., 2006; Niederkorn, 2006). A fourth pathway involves activation of IL-1 receptors located on perivas- cular macrophages and endothelial cells of brain venules resulting in production of prostaglandin E2 by upregulation of cyclooxygenase (COX) enzyme synthe- sis (Pasinetti, 1998; Lacroix and Rivest, 1998;Lietal.,2001; Konsman et al., 2004; Sapirstein et al., 2005; Inoue et al., 2006). These prostaglandins will dif- fuse to the brain targets where they will alter the setpoint for various regulatory processes (Dantzer et al., 2007). However, it was noted that not all of the effects of prostaglandin E 2 were proinflammatory (Zhang and Rivest, 2001). Increased amounts of proinflammatory cytokines from the periphery lead to production of proinflammatory cytokines by microglia cells within the brain (Eikelenboom and Veerhuis., 1996; Hull et al., 1996; Becher et al., 2000; Calvo et al., 2005; Dantzer 362 J. Kasten-Jolly and D.A. Lawrence et al., 2007). The visible response to the increased proinflammatory cytokines in the brain is sickness behavior (Horai et al., 1998; Cartmell et al., 1999). Administration of LPS systemically to mice increases expression, both mRNA and protein, of IL-1β and other proinflammatory cytokines in the brain (Iwai et al., 2006). Also, administration of IL-1β or TNF-α to mice resulted in decreased motor activity, social withdrawal, reduced food and water intake, increased slow-wave sleep, and altered cognition (Campbell et al., 2007; Dantzer et al., 2008). IL-6 has been associated with fever and hippocampus associated cognitive impairment (Smith et al., 2007). Moreover, overexpression of IL-6 in a transgenic mouse model has demonstrated that increased IL-6 will cause astrocytosis and neurodegenera- tion (Campbell et al., 1993; Steffensen et al., 1994; Jafarian-Tehrani and Sternberg, 1999). IL-6 signals through the JAK1/STAT3 pathway, and it has been shown that LPS-induced plasma levels of IL-6 cause nuclear translocation of the tran- scription factor STAT3 in certain brain structures including the area postrema, the vascular organs of the lamina terminalis, and the subfornical organ, as well as the hypothalamic supraoptic nucleus (Rummel et al., 2004). The predominant CNS source of IL-6 is the activated astrocyte. IL-6 expression in astrocytes is regulated by proinflammatory factors (such as IL-1β and TNF-α), neurotransmitters, and second messengers (Van Wagoner and Benveniste, 1999). Expression of the proinflammatory cytokines is promoted through activation of NF-kB which is present in inactive form in the cytoplasm by its association with IκBα (Yabe et al., 2005). Proinflammatory cytokines may downregulate their own expression by increasing the expression of IκB or decreasing its proteolysis in cer- tain cells of the brain (Laflamme and Rivest, 1999). Inhibition of NF-κB activation and inhibition of IκBα degradation occurs via a mechanism involving α-melanocyte stimulating hormone (αMSH), which is a pro-opiomelanocortin (POMC) derivative (Ichiyama et al., 1999). In the CNS, increases in proinflammatory cytokines lead to increased forma- tion of reactive oxygen species (ROS) and upregulation of genes that produce toxic products, such as reactive nitrogen species (RNS) (Floyd, 1999; Patel et al., 2003). Synthesis of nitric oxide (NO), can be induced in the brain by mediators of inflam- mation present in the cerebrospinal fluid (Kong et al., 2000). Several reports have indicated that IL-1 can induce nitric oxide synthase (iNOS) gene expression and thus promote the formation of NO through regulation by interleukin-1 converting enzyme (ICE, caspase-1) (Jones et al., 2005; Juttler et al., 2007). In summary, acti- vated glial cells release NO through increased expression of iNOS, upregulated by the presence of high concentrations of proinflammatory cytokines (Kifle et al., 1996; Stasiolek et al., 2000). Formation of ROS and NRS moieties can alter protein, DNA, RNA, lipid, and carbohydrate structures. Thus, unregulated inflammation can cul- minate in pathological impairment of normal functions; with disregulated oxidative stress, inhibition of mitochrondrial respiration can occur resulting in cytotoxicity (Brown and Bal-Price, 2003). It has been found that nitric oxide production can be inhibited by β- and γ-melanocortin in the mouse brain (Muceniece et al., 2004). CNS Cytokines 363 1.1.2 IL-18 Data from human and rodent studies have shown that IL-18 (previously referred to as interferon-gamma inducing factor, IGIF) expression can be associated with neuropathology in infection, autoimmune disease, ischemia, or closed head injury (Felderhoff-Mueser et al., 2005). IL-18 is a member of the IL-1 family of cytokines. Like IL-1β, it is synthesized as an inactive precursor protein (24 kDa) that is subsequently cleaved to the active18 kDa protein by caspase-1(ICE) (Nhan et al., 2006). The active form of IL-18 induces signal transduction by binding to its receptor, IL-18α/β receptor (IL1Rrp/IL1RAPL) expressed by diverse cell types, including neurons and glia cells. In adult brains of untreated BALB/c mice, IL-18 is constitutively the most highly expressed cytokine (Fig. 1). In the developing brain, IL-18 has been found in association with hypoxic-ischemic brain injury. Mice lacking IL-18 expression had smaller infarct size and a lesser extent of subcortical white matter injury (Felderhoff-Mueser et al., 2005). In a hypoxia model, IL-18 was associated with increased neuronal apoptosis. Therefore, IL-18 can exhibit neuropathology with respect to neuroinflammation and neurodegeneration. In experiments performed on the rat dentate gyrus, in vitro, IL-18 was found to Fig. 1 Constitutive expression of CNS cytokines. RNA from brains of male and female BALB/c mouse pups at 21 days of age was quantified by real-time RT-PCR. Whole-brain RNA was isolated using the Qiagen Lipid Tissue Midi RNA isolation kit. Brains were pooled by gender within each litter. Cytokine mRNA quantity was normalized to endogenous control GAPDH. Each bar repre- sents mean ± S.D. for N of 3 L. All of the cytokine levels significantly (p < 0.05) differed from each other except the following: IL-6:TNFα, IL-13:IFNγ,andTNFα:IFNγ; LT-β from IL-5, IL-6, IL-11, IL-13, TNFα,andIFNγ 364 J. Kasten-Jolly and D.A. Lawrence impair the induction of long-term-potentiation ( LTP) in NMDA receptor expressing neurons (Curran and O’Connor, 2001). Increased levels of IL-18 have now been reported to be present in the neurodegenerative disorder, Alzheimer’s disease (AD) (Bossu et al., 2008) and have been found associated with stress activation of brain microglia (Sugama et al., 2007). Human and mouse studies have shown that IL-1β and IL-18 are key players in fundamental inflammatory processes that increase during aging (Bodles and Barger, 2004; Joseph et al., 2005; Dinarello, 2006). Further evidence of the role of IL-18 in neuroinflammation is the finding that caspase-1 deficiency reduces inflammation- mediated transcription in the brain ( Mastronardi et al., 2007). In normal brain tissue caspase-1 is activated within molecular platforms called inflammasomes. Key proteins of inflammasomes are proteins containing caspase recruitment domains (CARDS), or pyrin domains (PYDS). CARD-only proteins are termed COPs and PYD-only proteins are termed POPs. These proteins modulate the inflammasome activity in response to pathogen infection and tissue destruction (Stehlik and Dorfleutner, 2007). For example, caspase-1 activation can be blocked by COPs, Iceberg, and COP1/Pseudo-ICE, with a CARD similar in sequence to caspase-1. Expression of Iceberg in monocytes abrogates the secretion of IL-1β in response to LPS stimulation. Because IL-18 is constitutively expressed at a high level in the adult mouse brain, it is possible that the noncleaved IL-18 proprotein may have a completely different function in the brain than the cleaved inflammation associated form. Such a precedent exists with IL-16. The uncleaved whole IL-16 molecule has neuronal activity (Kurschner and Yuzaki, 1999), whereas the truncated (cleaved by caspase-3) secreted IL-16 is a chemoattractant factor for CD4 + cells (Cruikshank et al., 2000). 1.1.3 Transforming Growth Factor-Beta (TGF-β) Reports on the activities of transforming growth factor-β1(TGFβ1) in the CNS have been conflicting in nature with some investigators describing anti-inflammatory effects and others indicating that TGFβ1 can have proinflammatory actions. Normal CNS concentrations of TGFβ1 are relatively high (Fig. 1), and it has been shown to be a potent neurotrophic cytokine with immunosuppressive properties. In the healthy adult brain, TGFβ1 inhibits proliferation of microglial and astrocyte cells. It has been suggested that the relatively high levels of TGFβ1 in the normal adult brain have some important function(s) in maintenance of neuronal growth and neuroim- mune function. Mice deficient in TGFβ1 displayed neuroinflammation throughout the brain, excessive astrogliosis, and proliferating microglia displaying a phago- cytic, deramified, and abnormally activated phenotype (Makwana et al., 2007). Ultrastructural features of TGFβ1 deficiency showed focal blockade of axonal trans- port, perinodal damming of axonal organelles, focal demyelination, and myelin debris in granule-rich phagocytic microglia cells. In a ME7 model of a murine prion disease, removal of TGFβ1 resulted in severe cerebral inflammation, increased expression of iNOS, and acute neuronal death in diseased animals. The data indicate a critical role for TFGβ1 in regulation of microglia cells and minimization of brain inflammation in order to avoid further brain tissue damage (Boche et al., 2006). . called in ammasomes. Key proteins of in ammasomes are proteins containing caspase recruitment domains (CARDS), or pyrin domains (PYDS). CARD-only proteins are termed COPs and PYD-only proteins are. producing proinflammatory cytokines. These cytokines then enter the brain by volume diffusion. Third, the overflow of cytokines in the systemic circulation can gain entry to the brain via cytokine. mechanism involving α-melanocyte stimulating hormone (αMSH), which is a pro-opiomelanocortin (POMC) derivative (Ichiyama et al., 1999). In the CNS, increases in proinflammatory cytokines lead to increased